P3 Health Partners (PIII) Earnings Analysis
P3 Health Partners (PIII) next reports earnings on 2026-08-10, consensus EPS -1.895 USD. Last quarter (2026-05-14) it beat with EPS 0.32 USD vs -4.85 USD est (+106.6%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -0.26.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PIII next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -1.895 USD |
| Revenue estimate | 0.38B |
PIII earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 0.32 USD | -4.85 USD | +106.6% | Beat |
| 2026-03-26 | -23.02 USD | -8.06333 USD | -185.5% | Miss |
| 2025-11-14 | -9.67 USD | -5.2925 USD | -82.7% | Miss |
| 2025-08-14 | -6.23 USD | -3.29 USD | -89.4% | Miss |
| 2025-05-15 | -6.28 USD | -5 USD | -25.6% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
PIII valuation and analyst view
| Trailing P/E | -0.26 |
|---|---|
| Trailing EPS | -38.39568 USD |
| Price / book | -0.23 |
| Dividend yield | 0.00% |
| Market cap | 0.03B |
| Analyst consensus | Buy (2 buy / 2 hold / 0 sell) |
| Avg price target | 14 USD |
Related research pages
Frequently asked questions
When is P3 Health Partners (PIII)'s next earnings date?
P3 Health Partners is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -1.895 USD and revenue estimate of 0.38B.
Did PIII beat earnings last quarter?
In its 2026-05-14 report, PIII posted EPS of 0.32 USD versus a -4.85 USD estimate — a beat of 106.6%.
What is PIII's earnings track record?
Over the last 5 reported quarters with consensus data, PIII beat estimates 1 times (20%).
What is PIII's current P/E ratio and EPS?
PIII trades at a trailing P/E of -0.26 on trailing EPS of -38.39568126520681 USD.
What do analysts rate PIII?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 14 USD.